WO2021141368A2 - 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물 - Google Patents
세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2021141368A2 WO2021141368A2 PCT/KR2021/000102 KR2021000102W WO2021141368A2 WO 2021141368 A2 WO2021141368 A2 WO 2021141368A2 KR 2021000102 W KR2021000102 W KR 2021000102W WO 2021141368 A2 WO2021141368 A2 WO 2021141368A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- bioactive
- macular degeneration
- carrier peptide
- present
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Definitions
- the present invention relates to a composition for preventing or treating macular degeneration containing a cell-permeable nucleic acid complex as an active ingredient, and more particularly, to a cell-permeable nucleic acid complex in which a bioactive nucleic acid targeting the NLRP3 gene and a carrier peptide nucleic acid are complementary to each other. It relates to a pharmaceutical composition for prevention, improvement or treatment of macular degeneration containing.
- Macular degeneration one of the three major blindness diseases along with glaucoma and diabetic retinopathy, is largely classified into wet (exudative) macular degeneration and dry (non-exudative) macular degeneration.
- the macula a nervous tissue located at the center of the retina, plays an important role in vision.
- dry macular degeneration is a disease in which retinal and choroid atrophy due to the accumulation of drusen with age. Although it does not affect vision, it is caused by wet macular degeneration. It is a progressive disease that requires attention.
- the treatment of dry (non-exudative) macular degeneration involves taking antioxidant vitamins known to slow the progression of macular degeneration, treatment for high blood pressure and hyperlipidemia, which are risk factors for macular degeneration, and lifestyle treatments such as smoking and UV protection.
- dry (non-exudative) macular degeneration progresses to wet (exudative) macular degeneration
- active treatment is required to preserve vision.
- Thermal laser photocoagulation is performed when the boundaries of the area where degeneration has occurred, and photodynamic therapy, antibody injection, and vitrectomy are performed, but there is no complete treatment yet, and active research is ongoing.
- Anti-VEGF antibody an anti-vascular endothelial growth factor antibody
- Representative drugs include aflibercept (Eylia), ranibizumab (Lucentis), and bevacizumab (Avastin).
- aflibercept Esylia
- ranibizumab Ranibizumab
- Avastin bevacizumab
- NLRP3 is a protein involved in the inflammatory response, and plays a major role in the expression of IL-1 ⁇ and IL-18.
- NLRP3 NOD-like receptor family, pyrin domain-containing 3
- the inflammasome is a sensor protein, NLRP3 (NOD-like receptor family, pyrin domain-containing 3); ASC (adaptor protein apoptosis-associated spec-like protein containing a caspase-recruitment domain), which is an adapter protein; and pro-caspase-1, an effector protein.
- Inflammasome activated by assembly activates caspase-1 and secretes IL-1_ or IL-18 to induce an inflammatory response.
- the association between NLRP3 inflammasome activation and retinal disease has been previously reported in several literatures (Lucia Celkova, et al., NLRP3 Inflammasome and Pathobiology in AMD, J Clin Med. 2015 Jan; 4 (1): 172-192).
- dry (non-exudative) macular degeneration is characterized by the presence of excessive amounts of drusen, and Sarah Doyle and Matthew Campbell found that drusen accumulated in the macula can lead to the production of IL-18 and IL-1 ⁇ through an inflammatory response.
- IL-18 can progress from dry macular degeneration to wet macular degeneration.
- NLRP3 is associated with accumulation of AluRNA and loss of Dicer-1, and activation of caspase-1 along with NLRP3 inflammasome causes retinal pigment epithelial degeneration, which is very similar to geographic atrophy in vivo. It has been reported to show one aspect (Valeria Tarallo et al., Cell 2012 May 11;149(4):847-59).
- nucleic acid drugs inhibit the expression of target-specific messenger RNA (mRNA), making it possible to address research areas that were impossible to treat with conventional drugs targeting proteins (Kole R. et al. Nature Rev. Drug Discov. 2012; 11; 125-140., Wilson C. et al. Curr. Opin. Chem. Bio. 2006; 10: 607-614.).
- mRNA messenger RNA
- Various clinical trials using nucleic acids are in progress due to their performance and advantages as drugs, and despite the increasing use of nucleic acid-based therapeutics, the use of carriers for intracellular introduction is extremely limited.
- nucleic acids are mainly through administration routes such as intramuscular injection, ocular administration, and subcutaneous injection, which are parenteral methods without including a delivery system.
- the cell membrane penetration ability of the oligonucleic acid itself is quite low, and in particular, since DNA or RNA has a negative charge, it cannot pass through the hydrophobic phospholipid bilayer of the cell, and thus intracellular delivery through simple diffusion is difficult.
- viral carriers such as retroviruses or adeno-associated virus (AAV) enables the introduction of oligonucleic acids into cells, but there are risks such as unintended immune activity and the possibility of recombination of oncogenes. (Couto LB et al. Curr. Opin. Pharmacol. 2010, 5; 534-542.).
- This nucleic acid delivery technique has a functional residue in direct binding, includes a step for complex formation, and has problems such as endosome escape efficiency and biotoxicity of the liposome structure. It is necessary to improve the introduction function and solve the problems related to the manufacturing procedure and side effects.
- the present inventors have found that the cell permeability of a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid modified to have a positive charge as a whole are complementarily bound to each other is surprisingly improved, and using this It has been confirmed that the expression of the target gene can be very efficiently regulated, and a patent has been registered for a new construct with low cytotoxicity, improved cell permeability of bioactive nucleic acids and improved gene expression control ability (Korean Patent No. 10- 1963885).
- the present inventors found a carrier peptide nucleic acid modified to have a positive charge as a whole with a bioactive nucleic acid (Bioactive Nucleic Acid). ), the nucleic acid complex to which this complementarily bound has the property of passing through the skin and cells very efficiently, confirming that this nucleic acid complex has excellent cell permeability.
- Bioactive Nucleic Acid Bioactive Nucleic Acid
- the present inventors have made diligent efforts to develop a nucleic acid complex that can effectively treat macular degeneration by a simple method such as administration of eye drops without direct injection by improving ocular cell permeability.
- bioactive nucleic acids targeting the NLRP3 gene It was found that the cell-permeable nucleic acid complex in which a carrier peptide nucleic acid and a carrier peptide nucleic acid are complementary to each other exhibits an excellent effect in preventing or treating macular degeneration, thereby completing the present invention.
- An object of the present invention is to provide a pharmaceutical composition for preventing, improving or treating macular degeneration, which contains a nucleic acid complex having high cell permeability and excellent preventive or therapeutic effect on macular degeneration as an active ingredient.
- the present invention provides a bioactive nucleic acid targeting the NLRP3 gene (Bioactive Nucleic Acid); And carrier peptide nucleic acid (Carrier Peptide Nucleic Acid) provides a pharmaceutical composition for the prevention, improvement or treatment of macular degeneration containing a cell-permeable nucleic acid complex complementarily bound as an active ingredient.
- the present invention also provides a method for preventing or treating macular degeneration comprising administering the cell-permeable nucleic acid complex.
- the present invention also provides the use of the cell-permeable nucleic acid complex for the prevention or treatment of macular degeneration.
- the present invention also provides the use of the cell-permeable nucleic acid complex for the manufacture of a medicament for the prevention or treatment of macular degeneration.
- Figure 2a shows the results of analysis by immunocytochemical staining to confirm the change in NLRP3 expression over time (day 1, day 3, and day 5) after the nucleic acid complex of Table 5 was treated with a dry human-derived retinal pigment epithelial cell line.
- Figure 2b is immunocytochemistry confirming the change in the expression of the sub-step gene (Caspase-1) according to time (day 1, day 3, and day 5) after treatment of the nucleic acid complex of Table 5 in a dry human-derived retinal pigment epithelial cell line; It is the result of analysis by staining method.
- FIG. 3 is a photograph of retinal tissue observed with a light microscope 2 weeks after administration of an eye drop containing the nucleic acid complex of Table 6 in mice induced with macular degeneration.
- damage to the retinal pigment epithelial cells was suppressed, and the collapse of the extragranular layer and the inner granular layer was alleviated.
- 5A is a photograph of retinal tissue observed with a light microscope 2 weeks after administration of an eye drop containing the nucleic acid complex of Table 7 in mice induced with macular degeneration.
- 5B is a photograph of a retinal section confirmed 2 weeks after administration of an eye drop containing the nucleic acid complex of Table 7 in mice induced with macular degeneration.
- Macular degeneration remains the number one cause of blindness and threatens a healthy old life. Dry macular degeneration is classified into early, middle, and late macular degeneration according to the presence or absence of drusen, the size and number of drusen, and the presence and extent of geographic atrophy. It is known that about 10% of patients with dry macular degeneration progress to wet macular degeneration, which can eventually lead to blindness, so the development of a treatment for dry macular degeneration is very important. Currently, in the case of dry macular degeneration, taking antioxidant vitamins, treatment for high blood pressure and hyperlipidemia, which are risk factors for macular degeneration, and lifestyle treatment such as smoking and UV protection, rather than treatment of the disease, maintenance of the status quo and wet macular degeneration, etc. It is meaningful in suppressing the progression of the disease, and there is no effective treatment.
- a cell-permeable nucleic acid complex in which a bioactive nucleic acid targeting the NLRP3 gene and a carrier peptide nucleic acid are complementarily combined can be utilized for the prevention and treatment of macular degeneration.
- a cell-permeable nucleic acid complex in which a bioactive nucleic acid targeting the NLRP3 gene and a carrier peptide nucleic acid are complementarily combined with human retinal pigment
- a bioactive nucleic acid targeting the NLRP3 gene and a carrier peptide nucleic acid are complementarily combined with human retinal pigment
- the present invention in one aspect, a bioactive nucleic acid targeting the NLRP3 gene (Bioactive Nucleic Acid); And it relates to a pharmaceutical composition for preventing, improving or treating macular degeneration containing a cell-permeable nucleic acid complex to which a carrier peptide nucleic acid is complementarily bound as an active ingredient.
- the nucleic acid complex in which the bioactive nucleic acid and the carrier peptide are complementary to each other may have a structure of the following structural formula (1).
- A is a bioactive nucleic acid (Bioactive Nucleic Acid) having a sequence capable of binding to a desired gene
- C is a carrier peptide nucleic acid capable of binding to a bioactive nucleic acid (Carrier Peptide Nucleic Acid),
- ' ⁇ ' means complementary binding between the bioactive nucleic acid and the carrier peptide nucleic acid
- the bioactive nucleic acid represented by A has an overall negative charge or neutrality
- C(+) means that the carrier peptide nucleic acid has an overall positive charge
- the carrier peptide nucleic acid comprises one or more peptide nucleic acid monomers modified to be positively charged throughout the carrier peptide nucleic acid.
- the bioactive nucleic acid and the carrier peptide nucleic acid in the nucleic acid complex according to the present invention may have an anti-parallel binding or parallel binding form.
- the complementary binding form of the nucleic acid can be isolated in the presence of a target sequence (sequence complementary to the bioactive nucleic acid) of the bioactive nucleic acid.
- the carrier peptide nucleic acid preferably includes one or more gamma- or alpha-backbone-modified peptide nucleic acid monomers such that the entire carrier peptide nucleic acid has a positive charge, and the gamma- or alpha-backbone-modified peptide nucleic acid is nucleic acid. It is more preferable that the monomer contains more of the monomer having the amino acid having a positive charge than the monomer having the amino acid having the negative charge so that the overall charge of the carrier peptide nucleic acid is positive.
- the "bioactive nucleic acid” binds to a target gene and a nucleotide sequence including the same in vitro or in vivo, and the intrinsic function of the gene (eg, transcript transcript) expression or protein expression) to activate or inhibit, or to regulate splicing of pre-mRNA (eg, exon skipping), and the base sequence is It may be characterized in that it is a gene regulatory sequence, a gene coding sequence, or a splicing regulatory sequence,
- the bioactive nucleic acid is a bioactive nucleic acid whose expression is reduced.
- a nucleic acid having a complementary sequence capable of binding to a target gene of interest particularly a complementary sequence capable of binding to mRNA of the target gene, and a nucleic acid involved in gene expression regulation such as suppressing the expression of the gene means, and may be a nucleic acid having a sequence complementary to a target gene whose expression is to be reduced.
- bioactive nucleic acid in the present invention is preferably an antisense peptide nucleic acid of NLRP3 (NOD-like receptor family, pyrin domain-containing 3) gene, which is a related target gene of macular degeneration, more preferably may include the sequence of SEQ ID NO: 4 of Table 1, but is not limited thereto.
- NLRP3 NOD-like receptor family, pyrin domain-containing 3
- the bioactive nucleic acid is DNA, RNA, or modified nucleic acid, such as peptide nucleic acid (PNA), phosphorodiamidate morpholino oligonucleotide (PMO), locked nucleic acid (LNA), glycol nucleic acid (GNA) and threose nucleic acid (TNA), antisense It may be one selected from the group consisting of an antisense oligonucleotide, an aptamer, a small interfering RNA (siRNA), a short hairpin RNA (shRNA), a ribozyme, and a DNAzyme, preferably the bioactivity Nucleic acid is selected from the group consisting of DNA, RNA, or modified nucleic acids, such as peptide nucleic acid (PNA), phosphorodiamidate morpholino oligonucleotide (PMO), locked nucleic acid (LNA), glycol nucleic acid (GNA), and threose nucle
- carrier peptide nucleic acid refers to a nucleic acid that imparts functionality by complementary binding of a bioactive nucleic acid and some or all of its bases
- the carrier peptide nucleic acid used in the present invention is a peptide nucleic acid (PNA: Peptide).
- Nucleic Acid as well as similar modified nucleic acids can be used, and peptide nucleic acids are preferred, but not limited thereto.
- the carrier peptide nucleic acid is preferably represented by a sequence selected from the group consisting of SEQ ID NOs: 5 to 11 of Table 2, but is not limited thereto.
- the bioactive nucleic acid and the carrier peptide nucleic acid are phosphodiester, 2'0-methyl (2'0-methyl), 2' methoxy-ethyl (2' methoxy-ethyl), phosphor It may be characterized in that it further comprises at least one functional group selected from the group consisting of amidate (phosphoramidate), methylphosphonate (methylphosphonate) and phosphorothioate (phosphorothioate).
- the "cell-permeable nucleic acid complex” is capable of penetrating a bioactive substance into the body and ultimately into a cell through extracellular treatment, and specifically, capable of delivering a bioactive nucleic acid targeting the NLRP3 gene into the cell. have the ability
- the cell-permeable nucleic acid complex may remain in the eye or may pass through cells and be delivered into the body.
- the nucleic acid complex may be characterized as having ocular persistence.
- the "cell-permeable nucleic acid complex" is, in addition to direct administration into cells, intraocular instillation, intraretinal administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration
- it has the property of being able to be delivered into a desired cell or into an ocular cell through administration, intrapulmonary administration, rectal administration or transdermal administration, and may be used in any form containing the nucleic acid complex.
- the cell-permeable nucleic acid complex is a bioactive nucleic acid represented by SEQ ID NO: 2; and a carrier peptide nucleic acid represented by any one sequence selected from the group consisting of SEQ ID NOs: 3 to 7, but is not limited thereto.
- the binding force (melting temperature, Tm) of the bioactive nucleic acid targeting the NLRP3 gene and the carrier peptide nucleic acid is lower than the binding force between the bioactive nucleic acid and the NLRP3 gene, a target of the bioactive nucleic acid.
- the binding force is the bioactive nucleic acid and the carrier peptide nucleic acid by parallel binding or partial specific binding according to the 5'-direction and the 3'-direction of each nucleic acid, whereby the bioactive nucleic acid and the carrier peptide nucleic acid
- the binding force (melting temperature, melting temperature, Tm) of the bioactive nucleic acid may be lower than the binding force between the bioactive nucleic acid and the target gene of the bioactive nucleic acid.
- the bioactive nucleic acid or carrier peptide nucleic acid may be characterized in that a substance that helps endosomes escape is additionally bound to the 5'-end or 3'-end of each nucleic acid. That is, it may be characterized in that it has the structure of the following structural formula (2) by further including a substance that helps the endosome escape of the bioactive nucleic acid and the carrier peptide nucleic acid.
- 'm' refers to a substance that helps the endosome escape of the bioactive nucleic acid and the carrier peptide nucleic acid.
- the "substance that helps endosomes escape” is characterized in that it helps the escape of the bioactive nucleic acids from the endosomes by increasing the osmotic pressure inside the endosomes or destabilizing the membranes of the endosomes. have. It means that bioactive nucleic acids move more efficiently and quickly into the nucleus or cytoplasm to meet and act on target genes (DW Pack, AS Hoffman, S. Pun, PS Stayton, "Design and development of polymers for gene delivery,” Nat. Rev. Drug. Discov., 4, 581-593 (2005)).
- the material helping the endosomes escape is a peptide, lipid nanomaterials, conjugate nanomaterials (polyplex nanoparticles), polymer nanospheres, inorganic nanomaterials (inorganic nanoparticles), cationic lipids It may be characterized in that at least one selected from the group consisting of nanomaterials (cationic lipid-based nanoparticles), cationic polymers and pH sensitive polymers.
- a peptide may be linked to a bioactive nucleic acid as a substance that helps the endosomal escape through a linker, and Histidine (10) is linked to a carrier peptide nucleic acid via a linker. It may be characterized by combining, but is not limited thereto.
- the lipid nanomaterial may be characterized in that it is selected from the group consisting of Lipid, phospholipids, acetyl palmitate, poloxamer 18, Tween 85, tristearin glyceride and Tween 80.
- the conjugate nanomaterial may be characterized in that poly(amidoamine) or polyethylenimine (PEI).
- the polymer nanospheres are selected from the group consisting of polycaprolactone, poly(lactide-co-glycolide, polylactide, polyglycolide, poly(d,l-lactide), chitosan and PLGA-polyethylene glycol. can be characterized.
- the inorganic nanomaterial may be characterized in that selected from the group consisting of Fe2O3 Fe3O4, WO3 and WO2.9.
- the cationic lipid-based nanoparticles are 1-(aminoethyl)iminobis[N-(oleicylcysteinyl-1-amino-ethyl)propionamide], N-alkylated derivative of PTA and 3,5- It may be characterized in that it is selected from the group consisting of didodecyloxybenzamidine.
- the cationic polymer is selected from the group consisting of vinylpyrrolidone-N, N-dimethylaminoethyl methacrylate acid copolymer diethyl sulphate, polyisobutylene and poly(N-vinylcarbazole). It may be characterized.
- the pH sensitive polymers may be selected from the group consisting of polyacids, poly(acrylic acid), poly(methacrylic acid) and hydrolyzed polyacrylamide.
- the bioactive nucleic acid and the carrier peptide nucleic acid each comprise 2 to 50, preferably 5 to 30, more preferably 10 to 25, most preferably 15 to 17 nucleic acid monomers.
- the bioactive nucleic acid may be characterized in that it consists of a natural nucleic acid base and/or a modified nucleic acid monomer.
- the monomer used for the bioactive nucleic acid is PNA, it is called a bioactive nucleic acid, and when other monomers are used, it is called in the same manner.
- the bioactive nucleic acid and the carrier peptide nucleic acid are phosphodiester, 2' 0-methyl (2' 0-methyl), 2' methoxy-ethyl (2' methoxy-ethyl), phosphor It may be characterized in that it further comprises any one or more functional groups selected from the group consisting of amidate (phosphoramidate), methylphosphonate (methylphosphonate) and phosphorothioate (phosphorothioate).
- the carrier peptide nucleic acid may be characterized in that part or all of the nucleotide sequence is complementary to the bioactive nucleic acid.
- the carrier peptide nucleic acid may include one or more universal bases, and all of the carrier peptide nucleic acids may consist of the universal base.
- each of the bioactive nucleic acid and the carrier peptide nucleic acid in the cell-permeable nucleic acid complex may be a complex, characterized in that the overall electrical properties have a positive charge (positive), a negative charge (negative) or a neutral charge.
- the meaning of “total” means the overall electrical properties when viewed from the outside, and the charge of the entire bioactive nucleic acid or carrier peptide nucleic acid is not the electrical property of individual bases, for example, Although some of the monomers in the sex nucleic acid are positive, if there is a greater number of negative monomers, the bioactive nucleic acid has a negative charge in electrical properties "as a whole", and some bases and/or bases in the carrier peptide nucleic acid Even if the backbone is negative, when the number of positive bases and/or backbones is greater, the carrier peptide nucleic acid has a positive charge in terms of electrical properties "as a whole".
- the nucleic acid complex of the present invention has a positive charge as a whole.
- the bioactive nucleic acid has a negative charge or a neutral property in view of the overall electrical properties
- the carrier peptide nucleic acid has a positive charge property in view of the overall electrical property.
- the present invention is not limited thereto.
- a modified peptide nucleic acid monomer may be used for imparting electrical properties between the bioactive nucleic acid and the carrier peptide nucleic acid, and the modified peptide nucleic acid monomer is a carrier peptide nucleic acid having a positive charge.
- Lysine (Lysine, Lys, K) , Arginine (Arginine, Arg, R), histidine (Histidine, His, H), diamino butyric acid (Diamino butyric acid, DAB), ornithine (Ornithine, Orn) and any one or more positive charges selected from the group consisting of amino acid analogs
- a carrier peptide nucleic acid having a negative charge it may be characterized as comprising an amino acid of glutamic acid (Glutamic acid, Glu, E), which is a negatively charged amino acid, or a negatively charged amino acid of an amino acid analog.
- the carrier peptide nucleic acid may be characterized in that it comprises one or more gamma- or alpha-backbone modified peptide nucleic acid monomers to have a positive charge as a whole.
- the gamma- or alpha-backbone-modified peptide nucleic acid monomer is lysine (Lysine, Lys, K), arginine (Arginine, Arg, R), histidine (Histidine, His, H), diamino butyric acid to have an electrical positive acid, DAB), ornithine (Orn), and amino acids having a positive charge at least one selected from the group consisting of amino acid analogs may be characterized in that the backbone contains.
- the modification of the peptide nucleic acid monomer for charge imparting may use a nucleobase-modified peptide nucleic acid monomer in addition to the backbone modification.
- a nucleobase-modified peptide nucleic acid monomer in addition to the backbone modification.
- it may be characterized by including an amine, triazole, or imidazole moiety in the nucleobase so as to have an electronegativity, or a carboxylic acid in a base to have an electronegativity.
- the modified peptide nucleic acid monomer of the carrier peptide nucleic acid may further include a negative charge in the backbone or nucleobase, but the modified peptide nucleic acid monomer contains more of the monomer having a positive charge than the monomer having a negative charge. It is preferred that the charge of the nucleic acid be positive.
- the nucleic acid complex according to the present invention is characterized in that it has a positive charge as a whole.
- At least one substance selected from the group consisting of a hydrophobic moiety, a hydrophilic moiety, a target antigen-specific antibody, an aptamer, or a fluorescent/luminescent marker is a bioactive nucleic acid and/or may be characterized as bound to a carrier peptide nucleic acid, preferably the hydrophobic moiety, hydrophilic moiety, target antigen-specific antibody, aptamer and fluorescent/luminescent marker for imaging.
- One or more substances selected from the group consisting of, etc. may be bound to the carrier peptide nucleic acid.
- the binding of the carrier peptide nucleic acid may be characterized as a simple covalent bond or a covalent bond mediated by a linker, but is not limited thereto.
- the cell permeability, solubility, stability, transport and imaging-related substances (eg, hydrophobic residues, etc.) bound to the nucleic acid carrier exist independently of the bioactive nucleic acid that modulates the expression of the target gene.
- the complementary binding form of the bioactive nucleic acid and the carrier peptide nucleic acid is largely characterized in that it has the form of antiparallel binding and parallel binding.
- the complementary binding form has a structure that is separated in the presence of a target sequence (sequence complementary to the bioactive nucleic acid) of the bioactive nucleic acid.
- the antiparallel bond and the parallel bond are determined according to the 5'-direction and the 3'-direction in the binding method of DNA-DNA or DNA-PNA.
- Antiparallel binding is a general method of binding DNA-DNA or DNA-PNA.
- the bioactive nucleic acid is in the 5' to 3' direction
- the carrier peptide nucleic acid is in the 3' to 5' direction. It means a form that is coupled to each other in the direction.
- Parallel bond refers to a form in which binding force is somewhat lower than that of antiparallel bond, and refers to a form in which both the bioactive nucleic acid and the carrier peptide nucleic acid are bonded to each other in the 5' to 3' direction or 3' to 5' direction.
- the binding force of the bioactive nucleic acid and the carrier peptide nucleic acid is lower than the binding force of the bioactive nucleic acid and the bioactive nucleic acid to a target gene, in particular, mRNA of the target gene.
- the bonding strength is determined by melting temperature, melting temperature or Tm.
- Examples of a specific method for making the binding force (melting temperature, Tm) of the bioactive nucleic acid and the carrier peptide nucleic acid lower than the binding force of the bioactive nucleic acid and the bioactive nucleic acid with a target gene, particularly the mRNA of the target gene, include,
- the bioactive nucleic acid and the carrier peptide nucleic acid may be characterized in parallel binding or partial specific binding, but is not limited thereto.
- the carrier peptide nucleic acid has at least one peptide nucleic acid base selected from the group consisting of a linker, a universal base, and a peptide nucleic acid base having a base that is not complementary to a corresponding base of the bioactive nucleic acid. can be, but is not limited thereto.
- the universal base binds without selectivity with natural bases such as adenine, guanine, cytosine, thymine, and uracil, and is complementary
- natural bases such as adenine, guanine, cytosine, thymine, and uracil
- At least one selected from the group consisting of inosine PNA, indole PNA, nitroindole PNA, and abasic as a base having a lower binding force than the binding force may be used, preferably It may be characterized by using inosine PNA.
- the combination of the binding form and electrical properties of nucleic acids for controlling the function of the nucleic acid complex is provided, and the particle size and time of action are controlled by the combination of the binding form and electrical properties of the nucleic acid, and cell permeability, solubility and specificity It can be characterized by improving the degree.
- the time point at which the bioactive nucleic acid is combined with the target sequence in the presence of the target gene (the point at which the bioactive nucleic acid is replaced with the target sequence, the target specificity separation and binding time), etc. can be controlled.
- the control of the time of strand displacement and target specific release and binding of the bioactive nucleic acid to the target gene is a carrier peptide for non-specific binding of the complex. It may be characterized in that it can be controlled by the presence, number and position of non-specific bases, universal bases, and linkers of nucleic acids. It may be characterized in that it can be controlled by a combination of the above conditions, such as a parallel or antiparallel form of a complementary bond of the peptide complex.
- the particles of the nucleic acid complex may have a size of 5 nm to 300 nm, preferably 10 nm to 200 nm, and most preferably 15 nm to 100 nm.
- the particle size of the nucleic acid complex may be controlled by controlling the charge balance of the bioactive nucleic acid and the carrier peptide nucleic acid. Specifically, when the positive charge of the carrier peptide nucleic acid increases, the particle size decreases, but when the positive charge of the carrier peptide nucleic acid exceeds a certain level, the particle size increases. In addition, the particle size is determined by the appropriate charge balance with the overall carrier peptide nucleic acid according to the charge of the bioactive nucleic acid complexed as another important factor determining the particle size.
- the positive charge of the carrier peptide nucleic acid according to the present invention is 1 to 7 (meaning that 1 to 7 monomers having a positive charge are included), preferably 2 to 5, most preferably 2 to 3 and the charge of the bioactive nucleic acid is 0 to 5 negative charges, preferably 0 to 3 net charges of the charge balance.
- the nucleic acid complex can be prepared by hybridizing a bioactive nucleic acid and a carrier peptide nucleic acid under appropriate conditions.
- Hybridization in the present invention means that complementary single-stranded nucleic acids form a double-stranded nucleic acid. Hybridization may occur when complementarity between two nucleic acid strands is perfect (perfect match) or even when some mismatched bases are present. The degree of complementarity required for hybridization may vary depending on hybridization conditions, and in particular may be controlled by the binding temperature.
- Target gene of the present invention means a nucleic acid sequence (base sequence) to be activated, inhibited or labeled, has no difference from the term “target nucleic acid”, and is used interchangeably herein.
- the bioactive nucleic acid when a target nucleic acid (base sequence) containing a target gene is contacted (bound) with the complex in vitro or in vivo, the bioactive nucleic acid is separated from the carrier peptide nucleic acid. and exhibit biological activity.
- diseases that can be prevented or treated using the nucleic acid complex may be determined according to the target gene of the bioactive nucleic acid in the nucleic acid complex.
- the target gene of the bioactive nucleic acid may be characterized as NLRP3.
- the disease that can be prevented and treated using the nucleic acid complex in the present invention may preferably be macular degeneration, and the macular degeneration includes age-related macular degeneration, dry macular degeneration and wet macular degeneration, Most preferably, the nucleic acid complex of the present invention is capable of preventing, improving or treating Dry Macular Degeneration.
- the preventive and therapeutic effects on dry macular degeneration were confirmed, but the inflammasome, a caspase-1 activation complex protein complex related to NLRP3 protein, plays a major role in progressing from dry macular degeneration to wet macular degeneration.
- the therapeutic composition of the present invention can be used to prevent, improve or treat wet macular degeneration, in particular, to prevent the progression from dry macular degeneration to wet macular degeneration (Alexander G. Marneros, 9445-958, 2013). ; Lucia Celkova, et. al., Journal of Clinical Medicine 4(1), 172-192, 2015; Yerramothu, P., et al., Eye 32, 491-505, 2018)
- the term "therapeutic composition” may be used interchangeably with “pharmaceutical composition”, and the bioactive nucleic acid of the present invention and a carrier peptide nucleic acid binding to the nucleic acid It may include a nucleic acid complex comprising a nucleic acid complex as an active ingredient, and additionally, a therapeutic drug for treating a target disease is bound to the nucleic acid complex.
- the pharmaceutical composition When the pharmaceutical composition is formulated and administered, it may be administered in the form of a formulation produced by a conventional method.
- the form of the administered formulation may be, for example, eye drops, eye ointment, powder, granules, tablets, capsules, injections, ointments, and the like, and is preferably in the form of eye drops or skin delivery, but is not limited thereto.
- Such formulations can be prepared according to methods common in the art.
- a drop, spray, or gel form is possible, and as another method, it may be administered to the eye using liposomes. It can also be injected into the tear film through a pump-catheter system.
- it can be incorporated into, carried by, or attached to, contact lenses over the eye.
- the form contained in a sponge or cotton swab that can be applied to the ocular surface may be used, and a liquid spray that may be applied to the ocular surface may also be used.
- composition according to the present invention may be formulated in the form of eye drops, aqueous solutions, gels, ointments, creams, lotions, pastes, smears or patches.
- aqueous solution may be in the form of distilled water and a buffer solution.
- formulations may contain additives such as pharmaceutically acceptable carriers, excipients, adjuvants or diluents suitable for formulations in a form that can be applied to the eye or skin in addition to the active ingredient.
- additives such as pharmaceutically acceptable carriers, excipients, adjuvants or diluents suitable for formulations in a form that can be applied to the eye or skin in addition to the active ingredient.
- pharmaceutically acceptable refers to a composition that is physiologically acceptable and does not normally cause allergic reactions such as gastrointestinal disorders, dizziness, or similar reactions when administered to humans.
- carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- the pharmaceutical composition may further include a filler, an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, and a preservative.
- the pharmaceutical compositions of the present invention may also be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the formulation may be in the form of a sterile injectable solution or the like.
- carrier is defined as a compound that facilitates the addition of a nucleic acid complex into a cell or tissue.
- DMSO dimethylsulfoxide
- carrier facilitates the introduction of many organic compounds into cells or tissues of living organisms.
- diot is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but is diluted in water which will dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
- the substance containing the nucleic acid complex in the present invention can be administered to the patient as a pharmaceutical composition as such or in combination with other active ingredients as in combination therapy or mixed with suitable carriers or excipients.
- compositions suitable for use in the present invention include compositions in which the active ingredients are contained in amounts effective to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount of a compound effective to prolong the survival of the subject being treated or to prevent, alleviate or ameliorate the symptoms of a disease. Determination of a therapeutically effective amount is within the ability of one of ordinary skill in the art, particularly in light of the detailed disclosure provided herein.
- prevention refers to any action that prevents the onset of a disease or inhibits its progression by administration (or application) of a therapeutic composition comprising the cell-permeable nucleic acid complex.
- the term "improvement” refers to any action of at least reducing the degree of a parameter, for example, a symptom, related to a treated state of a disease by administration (or application) of a therapeutic composition comprising the cell-permeable nucleic acid complex. .
- treatment refers to any action in which symptoms of a disease are improved or cured by administration (or application) of a therapeutic composition comprising the cell-permeable nucleic acid complex.
- Suitable delivery reagents include, but are not limited to, for example, Mirus Transit TKO lipophilic reagent, lipofectin, lipofectamine, cellfectin, polycations (eg, polylysine), atelocollagen, nanoplexes, and liposomes.
- atelocollagen as a delivery vehicle for nucleic acid molecules is described in Minakuchi et al. Nucleic Acids Res., 32(13):e109 (2004); Hanai et al. Ann NY Acad Sci., 1082:9-17 (2006); and Kawata et al. Mol Cancer Ther., 7(9):2904-12 (2008).
- Exemplary interfering nucleic acid delivery systems are provided in US Pat. Nos. 8,283,461, 8,313,772, and 8,501,930.
- the cell-permeable nucleic acid complex may be administered (or applied) using a carrier such as liposome.
- a carrier such as liposome.
- the liposome may help to target the complex to a specific tissue, such as lymphoid tissue, or to selectively target an infected cell, and may also help increase the half-life of a composition comprising the complex.
- Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, and lamellar layers.
- the complex to be delivered is liposomes, either alone or to specific cells in combination with a molecule that binds to a predominant receptor in lymphoid cells, such as a monoclonal antibody that binds to the CD45 antigen, or in combination with other therapeutic compositions.
- liposomes filled or decorated with a given complex of the present invention to deliver the nucleic acid complex composition can be directed to the site of lymphocytes.
- Liposomes for use in accordance with the present invention are generally formed from standard vesicle-forming lipids, including neutral and negatively charged phospholipids and sterols such as cholesterol.
- lipids are selected in consideration of, for example, the stability of the liposome in the bloodstream, acid lability, and the size of the liposome.
- Various methods can be used for preparing liposomes. See, eg, Szoka, et al., Ann. Rev. Biophys. Bioeng., 9:467, 1980), and US Pat. Nos. 4,235,871, 4,501,728, 4,837,028 and 5,019,369).
- the present invention provides a bioactive nucleic acid targeting the NLRP3 gene (Bioactive Nucleic Acid); And it relates to a method for preventing or treating macular degeneration, comprising administering to a subject a cell-permeable nucleic acid complex to which a carrier peptide nucleic acid (Carrier Peptide Nucleic Acid) is complementarily bound.
- a bioactive nucleic acid targeting the NLRP3 gene Bioactive Nucleic Acid
- Carrier Peptide Nucleic Acid Carrier Peptide Nucleic Acid
- composition comprising the nucleic acid complex according to the present invention can be applied to the eye in an effective amount for the treatment of macular degeneration or to suppress (or alleviate) the symptoms of macular degeneration.
- the type of macular degeneration, the age and weight of the patient, the characteristics and severity of symptoms, the type of current treatment, the number of treatments, the application form and route, etc. may vary depending on various factors, and may be easily determined by experts in the field.
- the composition of the present invention may be applied together or sequentially with the aforementioned pharmacological or physiological components, and may also be applied in combination with an additional conventional therapeutic agent, or may be applied sequentially or simultaneously with the conventional therapeutic agent. These applications may be single or multiple applications.
- “individual” means a mammal suffering from or at risk of a condition or disease that can be alleviated, inhibited or treated by administering (applying) the cell-permeable nucleic acid complex according to the present invention, preferably a human. it means.
- the dosage (application amount) of the compound of the present invention to the human body may vary depending on the patient's age, weight, sex, administration (application) form, health status and disease level, and is based on an adult patient weighing 70 kg. In general, it is 0.001 to 1,000 mg/day, preferably 0.01 to 500 mg/day, and according to the judgment of a doctor or pharmacist, divided administration (applying) may be performed once or several times a day at regular time intervals. have.
- the toxicity and therapeutic efficacy of a composition comprising a cell permeable nucleic acid complex described herein is, for example, LD50 (lethal dose for 50% of the population), ED50 (dose having a therapeutic effect on 50% of the population) , can be estimated by standard pharmaceutical procedures in cell culture or laboratory animals to determine the IC50 (dose having a therapeutic inhibitory effect on 50% of the population).
- the dose ratio between toxicity and therapeutic effect is the therapeutic index, which can be expressed as the ratio between LD50 and ED50 (or IC50).
- Compounds exhibiting high therapeutic indices are preferred. Data obtained from these cell culture assays can be used to estimate a range of doses used in humans.
- the dosage or application of such compounds is preferably within a range of circulating concentrations that include the ED50 (or IC50) with little or no toxicity.
- administration of the present invention means the act of introducing the pharmaceutical composition of the present invention to an individual in any suitable method, and the administration route can be administered through various routes, either oral or parenteral, as long as it can reach the target tissue. have.
- the administration route of the pharmaceutical composition of the present invention may be administered through any general route as long as it can reach the target tissue.
- the pharmaceutical composition of the present invention is not particularly limited thereto, but depending on the purpose, intraocular instillation, intraretinal administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, intrapulmonary administration , can be administered intrarectally.
- the composition may be administered by any device capable of transporting the active agent to a target cell.
- the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, and the term "pharmaceutically effective amount" of the present invention means to treat or prevent a disease at a reasonable benefit/risk ratio applicable to medical treatment or prevention. It means a sufficient amount, and the effective dose level is the severity of the disease, the activity of the drug, the age, weight, health, sex, sensitivity of the patient to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion.
- the duration of treatment may be determined according to factors including drugs used in combination with or concurrently with the composition of the present invention and other factors well known in the medical field.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects.
- the dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction of the disease, the age, weight, sex, history, or the type of substance used as an active ingredient.
- the pharmaceutical composition of the present invention may be administered to mammals including humans at 10 to 100 mg/kg, more preferably 10 to 30 mg/kg, for one day, and the administration frequency of the composition of the present invention is Although not particularly limited thereto, it may be administered 1 to 3 times a day or administered several times by dividing the dose.
- the present invention provides a bioactive nucleic acid targeting the NLRP3 gene (Bioactive Nucleic Acid); And the carrier peptide nucleic acid (Carrier Peptide Nucleic Acid) to the use of the cell-permeable nucleic acid complex complementarily bound to the prophylaxis or treatment of macular degeneration.
- Bioactive Nucleic Acid Bioactive Nucleic Acid
- Carrier Peptide Nucleic Acid Carrier Peptide Nucleic Acid
- the macular degeneration may be dry macular degeneration or wet macular degeneration, and most preferably, dry macular degeneration.
- the present invention provides a bioactive nucleic acid (Bioactive Nucleic Acid) targeting the NLRP3 gene for the preparation of a medicament for the prevention or treatment of macular degeneration; And it relates to the use of a cell-permeable nucleic acid complex to which a carrier peptide nucleic acid (Carrier Peptide Nucleic Acid) is complementarily bound.
- Bioactive Nucleic Acid Bioactive Nucleic Acid
- Carrier Peptide Nucleic Acid Carrier Peptide Nucleic Acid
- the macular degeneration may be dry macular degeneration or wet macular degeneration, and most preferably, dry macular degeneration.
- the NLRP3 gene was used as a target gene.
- Peptide nucleic acids antisense PNA
- bioactive peptide nucleic acid used as a control of the present invention consists of the sequence shown in SEQ ID NOs: 1 and 2, and the bioactive peptide nucleic acid (antisense PNA) used to confirm the therapeutic effect of dry macular degeneration is the sequence It consists of the sequence represented by No. 3 to No. 4.
- the peptide nucleic acid-based bioactive nucleic acids used in this example the peptide GLFDIIKKIAESF (SEQ ID NO: 12) for helping the endosomal escape function of SEQ ID NOs: 1 and 3 was bound to 5', SEQ ID NOs: 2 and 4 are endosomes It was synthesized in a form without peptides that help escape function.
- Carrier peptide nucleic acid used in this Example except for SEQ ID NOs: 6 and 11, all of the peptides for helping endosomes escape function were bound to the 5' to 3' ends, and consist of the sequence described. Base sequences, monomer modifications and structures are shown in Table 3 below.
- Table 3 shows the sequence information of the bioactive nucleic acid and carrier peptide nucleic acid used as a control and the bioactive nucleic acid and carrier peptide nucleic acid used as a control to confirm the effect as a therapeutic agent for dry macular degeneration targeting the NLRP3 gene.
- Modification of the monomer is converted into lysine (Lysine, Lys, K, (+)) for electrically positive and glutamic acid (Glutamic acid, Glu, E, (-) for electrically negative). It was prepared to have a modified peptide backbone as indicated).
- Each bioactive nucleic acid and carrier peptide nucleic acid combination was hybridized under DMSO, and as a result, a complex including the bioactive nucleic acid and carrier peptide nucleic acid was prepared.
- Example 2 Analysis of the therapeutic effect of dry macular degeneration using a nucleic acid complex
- the therapeutic effect of dry macular degeneration was analyzed using a nucleic acid complex comprising a bioactive nucleic acid and a carrier peptide nucleic acid using the NLRP3 gene prepared according to Example 1 as a target gene.
- Example 2-1 Cell culture
- Human retinal pigment epithelium (ARPE-19, ATCC NO. CRL-2302) obtained from ATCC (American Type Culture Collection, USA) was treated with DMEM:F-12 culture medium (Dulbecco Modified Eagle Medium Nutrient Mixure F-12 (Ham), Gibco BRL, Grand Island, NY, USA) was added with 10% (v/v) fetal bovine serum, penicillin 100 units/ml, and streptomycin 100 ⁇ g/ml, and under the conditions of 37_, 5% (v/v) CO2 cultured.
- IL Interleukin
- LPS Lipopolysaccharide
- Example 2-2 Analysis of gene expression through Western blot assay
- the human-derived retinal pigment epithelial cell line was seeded at 1x105 in a 6-well plate, and after culturing for 24 hours, the experiment was performed under the conditions of Example 2-1 to process a complex containing a bioactive peptide nucleic acid and a carrier peptide nucleic acid, After incubation for 48, 72, 96, and 120 hours, 30 ⁇ L of RIPA buffer was added to each well to obtain protein lysate.
- Protein lysate is quantified by BCA assay kit (Thermo Fisher, USA), and 30 ⁇ g of protein is separated by size through electrophoresis, transferred to PVDF membrane, and the primary antibody, NLRP3 (abcam, USA) , ASC (SantaCruz Biotechnology, USA), procaspase-1, caspase-1 (SantaCruz Biotechnology, USA), proIL-1beta, IL-1beta (Abcam, USA) were treated at 1:1000 and left at 4°C for one day.
- BCA assay kit Thermo Fisher, USA
- NLRP3 and sub-stage gene expression changes in a dry macular degeneration-like cell model using IL-1alpha were analyzed, and the nucleic acid complex combinations used are the same as in Table 4.
- a human-derived retinal pigment epithelial cell line was seeded at 5x103 in an 8-well plate and cultured for 24 hours, followed by an experiment under the conditions of Example 2-1 to process a complex containing a bioactive peptide nucleic acid and a carrier peptide nucleic acid, , 48, 72 after incubation, fixed in 4% paraformaldehyde, and then blocked with 0.1% Triton X-100 and normal donkey serum, and the primary antibody NLRP3 (abcam, USA) and caspase-1 (SantaCruz Biotechnology, USA) were treated at 1:200 and left at 4°C for one day.
- NLRP3 and sub-stage gene expression changes in a dry macular degeneration-like cell model using LPS were analyzed, and the nucleic acid complex combinations used are the same as in Table 5.
- Example 3 Analysis of the treatment effect in NaIO 3 induced animal model similar to dry macular degeneration using a nucleic acid complex
- nucleic acid combinations whose effects were verified through Example 2 were selected and the phenotype and histological findings were analyzed in an animal model similar to dry macular degeneration using NaIO 3 , and the nucleic acid complex combinations used are shown in Table 6.
- Example 3-1 Experimental Animal Breeding and Experimental Design
- a 5-week-old male B6 mouse was used after acclimatization for a week.
- NaIO3 (Sigma, USA) 35mg/kg was intravenously injected to induce selective degeneration and damage of retinal pigment epithelial cells as one of the changes seen in macular degeneration.
- nucleic acid complexes (1, 2) were treated with eye drops at 60 ⁇ g / 1 drop once a day for the control group (nucleic acid complex 1) and the test drug group (nucleic acid complex 2) in the case of 60 ⁇ g / 1 drop once a day for 14 days, the experiment was divided into groups treated.
- the slide sections were prepared by fixing them in 4% paraformaldehyde and embedding them in paraffin.
- the slide sections were stained with Hematoxylin & Eosin (H&E) and retinal tissue was evaluated under an optical microscope.
- H&E Hematoxylin & Eosin
- the retinal pigment epithelial cells were damaged due to NaIO3 administration and the nuclei of photoreceptor cells located immediately above were concentrated in the outer nuclear layer and the inner nuclear layer. warping was observed. In the group treated with the nucleic acid complex using eye drops, it was confirmed that damage to the retinal pigment epithelial cells was inhibited, thereby inhibiting the collapse of the granular layer.
- Example 3-2 Effect of 4-week administration of nucleic acid complex (60ug) of NLRP3 target gene
- Example 3-1 the nucleic acid complex (1, 2) was treated with an eye drop at 60 ⁇ g/1 drop/1 day for 28 days to prevent damage to the retinal pigment epithelium.
- the slide sections were prepared by fixing them in 4% paraformaldehyde and embedding them in paraffin.
- the slide sections were stained with Hematoxylin & Eosin (H&E) and retinal tissue was evaluated under an optical microscope.
- H&E Hematoxylin & Eosin
- the retinal pigment epithelial cells were damaged due to NaIO 3 administration and the nuclei of photoreceptor cells located immediately above were concentrated in the outer nuclear layer and the inner nuclear layer. ), the bending phenomenon was observed. In the group treated with the nucleic acid complex using eye drops, it was confirmed that damage to the retinal pigment epithelial cells was inhibited, thereby inhibiting the warpage of the extragranular layer.
- Example 3-3 Analysis of the therapeutic effect of NaIO 3 induced animal model using a nucleic acid complex
- nucleic acid complexes (6, 7) of Table 7 were used to inhibit damage to the retinal pigment epithelium using eye drops.
- Nucleic acid complex No. 6 was administered at 30 ⁇ g / 1 drop / 1 day for 14 days
- Nucleic acid complex No. 7 was 30 ⁇ g / 1 drop / 1 day
- Nucleic acid complex No. 7-1 was 10 ⁇ g / 1 drop / 1 day
- nucleic acid In case of Complex 7-2 the inhibitory effect was confirmed by administering 5 ⁇ g / 1 drop / 1 day for 14 days.
- MCC950 InvivoGen, USA
- an NLRP3 inhibitor was orally administered daily for 14 days at a dose of 10 mg/kg.
- the slide sections were prepared by fixing them in 4% paraformaldehyde and embedding them in paraffin.
- the slide sections were stained with Hematoxylin & Eosin (H&E) and retinal tissue was evaluated under an optical microscope.
- H&E Hematoxylin & Eosin
- FIG. 5 it was observed that retinal degeneration was induced by inducing retinal pigment epithelial cell degeneration through oxidative stress by administration of NaIO 3 , and nucleic acid complex (PNA 7, 30 ⁇ g / 1 drop / 1). day), it was confirmed that the degeneration of retinal pigment epithelial cells was reduced compared to the positive control (PC).
- PC positive control
- PNA 7-1 10 ⁇ g / 1 drop / 1 day
- PNA 7-2 5 ⁇ g / 1 drop / 1 day
- the thickness of the outer nuclear layer in which the nuclei of photoreceptor cells are concentrated in the retina was significantly inhibited to confirm the treatment effect of dry macular degeneration.
- the cell-permeable nucleic acid complex in which a bioactive nucleic acid targeting NLRP3 according to the present invention and a carrier peptide nucleic acid are complementarily combined has high cell permeability, so it can be administered by various methods including eye drops or skin application in addition to direct injection. And, by suppressing the expression of NLRP3, it is useful for the prevention, improvement or treatment of macular degeneration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
- NLRP3 유전자를 표적으로 하는 생활성 핵산 (Bioactive Nucleic Acid); 및 캐리어 펩티드 핵산 (Carrier Peptide Nucleic Acid)이 상보적으로 결합된 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방, 개선 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 생활성 핵산은 서열번호 4의 서열로 표시되는 서열을 포함하는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 캐리어 펩티드 핵산은 서열번호 5 내지 11로 구성된 군에서 선택되는 서열로 표시되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 핵산 복합체는 서열번호 4로 표시되는 서열을 포함하는 생활성 핵산; 및 서열번호 5 내지 11로 구성된 군에서 선택되는 어느 하나의 서열로 표시되는 서열을 포함하는 캐리어 펩티드 핵산을 포함하는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 생활성 핵산 또는 캐리어 펩티드 핵산은 각각의 핵산의 5'-말단 또는 3'-말단에 엔도좀 탈출을 도와주는 물질이 추가로 결합된 것을 특징으로 하는 약학 조성물.
- 제5항에 있어서, 상기 엔도좀 탈출을 도와주는 물질은 펩티드, 지질 나노물질(lipid nanoparticles), 접합체 나노물질(polyplex nanoparticles), 고분자 나노구(polymer nanospheres), 무기물 나노물질(inorganic nanoparticles), 양이온 지질 나노물질(cationic lipid-based nanoparticles), 양이온 고분자(cationic polymer) 및 pH 감응 고분자(pH sensitive polymers)로 구성된 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는 약학 조성물.
- 6항에 있어서, 상기 펩티드는 GLFDIIKKIAESF(서열번호 12) 또는 Histidine(10)인 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 생활성 핵산은 전체적으로 음전하 또는 중성을 가지는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 캐리어 펩티드 핵산은 전체적으로 양전하를 가지는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 핵산 복합체는 전체적으로 양전하를 가지는 것을 특징으로 하는 약학 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180013947.4A CN115484986A (zh) | 2020-01-06 | 2021-01-06 | 用于预防或治疗黄斑变性的含有细胞可渗透的核酸复合物作为活性成分的组合物 |
CA3163848A CA3163848A1 (en) | 2020-01-06 | 2021-01-06 | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
US17/790,734 US20230070129A1 (en) | 2020-01-06 | 2021-01-06 | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
EP21738122.7A EP4088742A2 (en) | 2020-01-06 | 2021-01-06 | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
JP2022567023A JP7459298B2 (ja) | 2020-01-06 | 2021-01-06 | 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物 |
AU2021205373A AU2021205373B2 (en) | 2020-01-06 | 2021-01-06 | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200001256 | 2020-01-06 | ||
KR10-2020-0001256 | 2020-01-06 | ||
KR1020210000730A KR102572074B1 (ko) | 2020-01-06 | 2021-01-05 | 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물 |
KR10-2021-0000730 | 2021-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021141368A2 true WO2021141368A2 (ko) | 2021-07-15 |
WO2021141368A3 WO2021141368A3 (ko) | 2021-10-07 |
Family
ID=76788462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/000102 WO2021141368A2 (ko) | 2020-01-06 | 2021-01-06 | 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230070129A1 (ko) |
EP (1) | EP4088742A2 (ko) |
JP (1) | JP7459298B2 (ko) |
CN (1) | CN115484986A (ko) |
AU (1) | AU2021205373B2 (ko) |
CA (1) | CA3163848A1 (ko) |
WO (1) | WO2021141368A2 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US8283461B2 (en) | 2004-03-05 | 2012-10-09 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of RNAi agents |
US8313772B2 (en) | 2010-02-24 | 2012-11-20 | Arrowhead Madison Inc. | Compositions for targeted delivery of siRNA |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
KR101963885B1 (ko) | 2016-08-09 | 2019-04-01 | 주식회사 시선테라퓨틱스 | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2842034C (en) | 2011-07-18 | 2023-09-05 | University Of Kentucky Research Foundation | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
US20200345756A1 (en) * | 2017-10-10 | 2020-11-05 | University Of Virginia Patent Foundation | Compositions and methods for treating age-related macular degeneration and geographic atrophy |
KR102262260B1 (ko) * | 2018-02-08 | 2021-06-09 | 주식회사 시선테라퓨틱스 | 엔도좀 탈출능을 갖는 펩티드 핵산 복합체 및 이의 용도 |
KR102484332B1 (ko) * | 2018-02-08 | 2023-01-04 | 주식회사 시선테라퓨틱스 | 핵산 복합체를 함유하는 피부 투과성 전달체 및 이의 용도 |
US10869880B2 (en) * | 2018-06-26 | 2020-12-22 | The Regents Of The University Of California | Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor |
-
2021
- 2021-01-06 EP EP21738122.7A patent/EP4088742A2/en active Pending
- 2021-01-06 JP JP2022567023A patent/JP7459298B2/ja active Active
- 2021-01-06 CA CA3163848A patent/CA3163848A1/en active Pending
- 2021-01-06 AU AU2021205373A patent/AU2021205373B2/en active Active
- 2021-01-06 CN CN202180013947.4A patent/CN115484986A/zh active Pending
- 2021-01-06 WO PCT/KR2021/000102 patent/WO2021141368A2/ko unknown
- 2021-01-06 US US17/790,734 patent/US20230070129A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US8283461B2 (en) | 2004-03-05 | 2012-10-09 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of RNAi agents |
US8313772B2 (en) | 2010-02-24 | 2012-11-20 | Arrowhead Madison Inc. | Compositions for targeted delivery of siRNA |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
KR101963885B1 (ko) | 2016-08-09 | 2019-04-01 | 주식회사 시선테라퓨틱스 | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 |
Non-Patent Citations (18)
Title |
---|
ALEXANDER G., MARNEROS, vol. 9, 2013, pages 445 - 958 |
BUYENS K. ET AL., J. CONTROL RELEASE, vol. 158, 2012, pages 362 - 70 |
COUTO L.B. ET AL., CURR. OPIN. PHARMACOL., vol. 5, 2010, pages 534 - 542 |
D.W. PACKA.S. HOFFMANS. PUNP.S. STAYTON: "Design and development of polymers for gene delivery", NAT. REV. DRUG. DISCOV., vol. 4, 2005, pages 581 - 593, XP037925365, DOI: 10.1038/nrd1775 |
HANAI ET AL., ANN. NY ACAD. SCI., vol. 1082, 2006, pages 9 - 17 |
KAWATA ET AL., MOL. CANCER THER., vol. 7, no. 9, 2008, pages 2904 - 12 |
KOLE R. ET AL., NATURE REV. DRUG DISCOV., vol. 11, 2012, pages 125 - 140 |
LUCIA CELKOVA ET AL.: "NLRP3 Inflammasome and Pathobiology in AMD", J. CLIN. MED., vol. 4, no. 1, January 2015 (2015-01-01), pages 172 - 192, XP055424446, DOI: 10.3390/jcm4010172 |
LUCIA CELKOVA, JOURNAL OF CLINICAL MEDICINE, vol. 4, no. 1, 2015, pages 172 - 192 |
MINAKUCHI ET AL., NUCLEIC ACIDS RES., vol. 32, no. 13, 2004, pages e109 |
ROSSI, J. J. ET AL., GENE THER, vol. 13, 2006, pages 583 - 584 |
SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467 |
TRABULO S. ET AL., CURR. PHARM. DES., vol. 19, 2013, pages 2895 - 923 |
VALERIA TARALLO ET AL., CELL, vol. 149, no. 4, 11 May 2012 (2012-05-11), pages 847 - 59 |
WILSON C. ET AL., CURR. OPIN. CHEM. BIO., vol. 10, 2006, pages 607 - 614 |
YERRAMOTHU P. ET AL., EYE, vol. 32, 2018, pages 491 - 505 |
YOUSEFI A. ET AL., J. CONTROL RELEASE, vol. 170, 2013, pages 209 - 18 |
ZHI D. ET AL., BIOCONJUG. CHEM., vol. 24, 2013, pages 487 - 519 |
Also Published As
Publication number | Publication date |
---|---|
AU2021205373A1 (en) | 2022-08-25 |
US20230070129A1 (en) | 2023-03-09 |
EP4088742A2 (en) | 2022-11-16 |
JP2023509101A (ja) | 2023-03-06 |
CN115484986A (zh) | 2022-12-16 |
JP7459298B2 (ja) | 2024-04-01 |
CA3163848A1 (en) | 2021-07-15 |
WO2021141368A3 (ko) | 2021-10-07 |
AU2021205373B2 (en) | 2023-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7032577B2 (ja) | エンドソーム脱出能を有するペプチド核酸複合体及びその用途 | |
CN108350467B (zh) | 基因构建体 | |
WO2022065919A1 (ko) | 펩티드 핵산 복합체를 유효성분으로 함유하는 치매 예방 또는 치료용 조성물 | |
KR102156324B1 (ko) | 핵산 복합체를 유효성분으로 함유하는 혈관신생관련 질환 치료용 약학 조성물 | |
Li et al. | A new approach of delivering siRNA to the cornea and its application for inhibiting herpes simplex keratitis | |
WO2021141368A2 (ko) | 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물 | |
WO2021125762A1 (ko) | 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체를 유효성분으로 함유하는 치매 예방 또는 치료용 조성물 | |
WO2020096234A1 (ko) | 피부 투과성 핵산 복합체를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
US11713463B2 (en) | Compositions and methods for increasing expression of SCN2A | |
WO2019066519A1 (ko) | 결합 조직 성장 인자를 표적으로 하는 rna 복합체를 함유하는 노인성 황반변성의 예방 또는 치료용 약학 조성물 | |
KR102572074B1 (ko) | 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물 | |
WO2016068617A1 (ko) | 폴리올계 삼투압적 폴리디자일리톨 폴리머 유전자 전달체 및 이의 용도 | |
WO2022045763A1 (ko) | 세포 투과성 핵산 복합체를 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
WO2023132673A1 (ko) | 핵산 복합체를 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
WO2023132674A1 (ko) | 핵산 복합체를 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
WO2022080849A1 (ko) | Acta2 억제제를 유효성분으로 포함하는 망막 또는 맥락막 질환 치료용 조성물 | |
WO2022055320A1 (ko) | 표적화된 유전자 전달을 위한 아데노-부속 바이러스 벡터 | |
WO2023163562A1 (ko) | 핵산 복합체를 포함하는 알츠하이머병의 예방 또는 치료용 조성물 | |
WO2021075880A1 (ko) | 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물 | |
WO2023163563A1 (ko) | 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물 | |
KR102156323B1 (ko) | 피부 투과성 핵산 복합체를 유효성분으로 함유하는 건선의 예방 또는 치료용 조성물 | |
WO2022131745A1 (ko) | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 | |
WO2024101915A1 (ko) | 개선된 펩티드 핵산 복합체 | |
WO2022124739A1 (ko) | ROR-beta의 발현을 억제하는 비대칭 RNAi 유도용 핵산 분자 | |
WO2022131744A1 (ko) | 펩티드 핵산 복합체를 유효성분으로 함유하는 췌장암 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21738122 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3163848 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022567023 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021738122 Country of ref document: EP Effective date: 20220808 |
|
ENP | Entry into the national phase |
Ref document number: 2021205373 Country of ref document: AU Date of ref document: 20210106 Kind code of ref document: A |